Angle

 

£12,200,000

Secondary Fundraise

 

October 2017

Angle

 

£3,700,000

Acquisition of certain assets of Axela

 

October 2017

Amryt Pharma

 

€15,000,000

Secondary Fundraise

 

September 2017

Tissue Regenix

 

£23,000,000

Acquisition of CellRight Technologies

 

July 2017

Tissue Regenix

 

£40,000,000

Secondary Fundraise

 

July 2017

BioLineRx

 

$6,000,000

Upfront consideration Acquisition of Agalimmune

 

March 2017

Arix Bioscience

 

£100,000,000

IPO on London
Main Market

 

February 2017

Redx Pharma

 

£12,000,000

Secondary Fundraise

 

February 2017

Imugene

 

$3,200,000

Secondary Fundraise

 

October 2016

Novogen

 

Fairness opinion in association with
acquisition

 

October 2016

Oxford BioMedica

 

£11,500,000

Secondary Fundraise

 

September 2016

Lombard Risk

 

£8,300,000

Secondary Fundraise

 

June 2016

Angle

 

£10,200,000

Secondary Fundraise

 

June 2016

Skyepharma

 

Strategic advisory
project

 

May 2016

Juniper

 

Strategic advisory
project

 

May 2016

Redx Pharma

 

£10,000,000

Secondary Fundraise

 

March 2016

Oxford BioMedica

 

£8,100,000

Secondary Fundraise

 

February 2016

Perceptive Bioscience

 

£50,100,0000

Private Placement

 

February 2016

Mereo BioPharma

 

£76,500,0000

Private Placement

 

July 2015

Avacta

 

£22,000,000

Secondary Fundraise

 

July 2015

Lombard Risk

 

£4,000,000

Secondary Fundraise

 

May 2015

Oxford BioMedica

 

$50,000,000

Debt facility arrangement

 

May 2015

Clinigen

£135,000,000

Secondary Fundraise in
association with £225m
acquisition of IDIS

 

April 2015

Newron Pharmaceuticals

 

CHF 24,300,000

Secondary Fundraise

 

April 2015

OSE Pharma

 

€22,000,000

IPO on Euronext Paris

 

March 2015

Admedus

 

AUD$28,000,000

Secondary Fundraise

 

March 2015

      Ark Therapeutics

Disposal of all Trading
Assets, Reverse Takeover,
admission to trading on
Standard Segment of
Official List

March 2013 –
February 2015

Venture Life Group

 

£4,320,000

Secondary Fundraise

 

December 2014

BTG

£150,000,000

Secondary Fundraise in
association with
PneumRX acquisition

 

December 2014

Oxford BioMedica

 

£25,700,000

Secondary Fundraise

 

May 2014

Admedus

 

AUD$18,300,000

Secondary Fundraise

 

May 2014

Newron Pharmaceuticals

 

CHF 18,600,000

Secondary Fundraise

 

April 2014

Verona Pharma

 

£14,000,000

Secondary Fundraise

 

March 2014

Venture Life Group

 

£26,400,000

IPO on AIM London
and acquisition of
Biokosmes Srl

March 2014

Oxford BioMedica

 

£5,000,000

Secondary Fundraise

 

December 2013

BTG

£106,000,000

Secondary Fundraise in
association with EKOS &
TheraSphere acquisition

 

June 2013

Lombard Medical

 

£23,000,000

Secondary Fundraise

 

June 2013

Dysis Medical

 

£7,400,000

Private Placement

 

April 2013

Proximagen PLC

 

$554,700,000

Sale of company to
Upsher Smith

 

August 2012

Oxford BioMedica

 

£11,600,000

Secondary Fundraise

 

July 2012

London

WG Partners
85 Gresham Street
London
EC2V 7NQ

Sydney

WG Partners Pty Ltd.
Level 2 Unit 204
111 Harrington Street
Sydney
NSW 2000

Minneapolis

PO Box 653
Prior Lake
MN 55372
United States